GeoVax Labs: Promising Developments in COVID-19 Vaccine and Therapeutics Propel Buy Rating
Vernon Bernardino, an analyst from H.C. Wainwright, reiterated the Buy rating on GeoVax Labs (GOVX – Research Report). The associated ...
Biotech Stock Roundup: NVAX Q3 Results, SNDX Down on AML Data, RNA Surges on Study Data
Novavax incurred a third-quarter 2024 loss of 76 cents per share, narrower than the Zacks Consensus Estimate of a loss of 87 cents. In the year-ago quarter, the company reported a loss of $1.26 per ...